399 — Innovative Pharmaceutical Biotech Cashflow Statement
0.000.00%
Last trade - 00:00- HK$399.06m
- HK$2.38bn
- HK$6.59m
- 14
- 40
- 25
- 12
Annual cashflow statement for Innovative Pharmaceutical Biotech, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -222 | -212 | 36.4 | -255 | 98.7 |
| Depreciation | |||||
| Non-Cash Items | 190 | 191 | -60.8 | 234 | -112 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -5.16 | -6 | 9.88 | 1.36 | 4.28 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -36.2 | -25 | -12.3 | -17.6 | -8.28 |
| Other Investing Cash Flow Items | 50 | 0.013 | -0.001 | 0 | 0 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 50 | 0.013 | -0.001 | 0 | 0 |
| Financing Cash Flow Items | -0.116 | -0.127 | -0.084 | 5.8 | -0.011 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -9.48 | 10.6 | 7.3 | 14.9 | 10.3 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 5.88 | -13.9 | -4.91 | -2.75 | 1.74 |